Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients

Hepatology Research

Volumn 45, Issue 10, 2015, Pages E82-E88

  Tamaki, Nobuharu ^a   Kurosaki, Masayuki ^a   Kuno, Atsushi ^b   Korenaga, Masaaki ^c   Togayachi, Akira ^b   Gotoh, Masanori ^b   Nakakuki, Natsuko ^a   Takada, Hitomi ^a   Matsuda, Shuya ^a   Hattori, Nobuhiro ^a   Yasui, Yutaka ^a   Suzuki, Shoko ^a   Hosokawa, Takanori ^a   Tsuchiya, Kaoru ^a   Nakanishi, Hiroyuki ^a   Itakura, Jun ^a   Takahashi, Yuka ^a   Mizokami, Masashi ^c   Narimatsu, Hisashi ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Hepatocellular carcinoma; Liver fibrosis; WFA+ M2BP

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLYCOPROTEIN; MAC 2 BINDING PROTEIN; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ;

AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER INCIDENCE; CARCINOGENESIS; CASE CONTROL STUDY; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DIFFERENCE;

EID: 84945449548     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12466     Document Type: Article

References (32)

1. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
2. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
3. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: S152-60.
4. Namiki I, Nishiguchi S, Hino K et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 347-68.
5. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
6. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
7. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
8. Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
9. Friedrich-Rust M, Nierhoff J, Lupsor M et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19: e212-9.
10. Fujimoto K, Kato M, Kudo M et al. Novel image analysis method using ultrasound elastography for noninvasive evaluation of hepatic fibrosis in patients with chronic hepatitis C. Oncology 2013; 84(Suppl 1): 3-12.
11. Tamaki N, Kurosaki M, Matsuda S et al. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatol Res 2013; 6: 12179.
12. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
13. Lin ZH, Xin YN, Dong QJ et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.
14. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
15. Tamaki N, Kurosaki M, Tanaka K et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat 2013; 20: 72-6.
16. Masuzaki R, Tateishi R, Yoshida H et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-61.
17. Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-1979.e3.
18. Nunes D, Fleming C, Offner G et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.
19. Park LS, Tate JP, Justice AC et al. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 2011; 20: 2512-7.
20. Tamaki N, Kurosaki M, Matsuda S et al. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol 2013; 15: 15.
21. Yu ML, Lin SM, Lee CM et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006; 44: 1086-97.
22. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429-34.
23. Kuno A, Ikehara Y, Tanaka Y et al. Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. Clin Chem 2011; 57: 48-56.
24. Kuno A, Ikehara Y, Tanaka Y et al. A serum " sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065.
25. Toshima T, Shirabe K, Ikegami T et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP), for assessing liver fibrosis. J Gastroenterol 2014; 7: 7.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
27. Kuno A, Sato T, Shimazaki H et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013; 3: 201300010.
28. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563-70.
29. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
30. Kurosaki M, Izumi N. External validation of FIB-4: diagnostic accuracy is limited in elderly populations. Hepatology 2008; 47: 352; author reply -3.
31. Castera L, Foucher J, Bernard PH et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-35.
32. Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.